| Assessment Status |
Rapid Review Complete |
| HTA ID |
- |
| Drug |
Simeprevir |
| Brand |
Olysio® |
| Indication |
In combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients as part of a triple therapy regimen (co-administered with PegInterferon + Ribavirin) to treat hepatitis C virus (HCV) Genotypes 1 and 4 who are treatment naïve or have previously been treated. |
| Rapid review commissioned |
27/05/2014 |
| Rapid review completed |
11/07/2014 |
| Rapid review outcome |
Full pharmacoeconomic assessment not recommended when used in triple therapy with peg-interferon and ribavirin. |
